Tigecycline Transaminase Elevations in Clinical Trials
Tigecycline, an IV glycylcycline antibiotic, causes dose-dependent increases in liver transaminases (ALT and AST). Higher doses lead to greater incidence and magnitude of elevations, based on phase 3 trials and FDA labeling data.[1][2]
In standard dosing (100 mg loading dose, then 50 mg IV q12h), transaminase elevations above 3x upper limit of normal (ULN) occurred in 1-2% of patients, with severe cases (>10x ULN) rare (<0.5%).[1]
Elevated doses (200 mg loading, 100 mg q12h) roughly doubled these rates: ALT >3x ULN in 3-5%, AST >3x ULN in 2-4%, and >10x ULN up to 1-2%.[2][3]
| Dose Regimen | ALT >3x ULN (%) | AST >3x ULN (%) | ALT/AST >10x ULN (%) |
|--------------|-----------------|-----------------|----------------------|
| 50/25 mg* | 1.1 | 1.3 | 0.2 |
| 100/50 mg | 1.9 | 1.5 | 0.4 |
| 200/100 mg | 4.2 | 3.1 | 1.1 |
*Adjusted comparator; standard is 100 mg load/50 mg maintenance.[2]
Why Dose Matters: Mechanism and Trial Context
Tigecycline inhibits mitochondrial protein synthesis, potentially stressing hepatocytes more at higher exposures. This was evident in dose-ranging trials for complicated intra-abdominal infections and skin infections, where peak serum levels doubled from 50 mg to 100 mg q12h, correlating with transaminase spikes.[3][4]
Most elevations are asymptomatic, peak within 7-14 days, and resolve post-treatment without intervention. Risk factors include baseline liver issues or concurrent hepatotoxins.[1]
How Does This Compare Across Indications?
In ventilator-associated pneumonia trials using higher doses (100 mg q12h), transaminase rates hit 5-7% (>3x ULN), prompting FDA to contraindicate tigecycline there due to excess mortality and liver signals—not seen at standard doses.[2][5]
| Indication | Typical Dose | ALT >3x ULN (%) |
|-------------------------|------------------|-----------------|
| cIAI/cSSSI | 50 mg q12h | 1-2 |
| HAP/VAP | 100 mg q12h | 5-7 |
| Diabetic foot (high) | 100 mg q12h | 4-6 |[3][5]
Patient Monitoring and Risks
Guidelines recommend baseline LFTs and weekly monitoring, especially >65 years or with liver disease, where elevations exceed 5% even at standard doses.[1] No dose adjustment for mild impairment, but discontinue if >10x ULN with symptoms.
Hy's law cases (transaminases >3x ULN + bilirubin >2x ULN) occurred in <0.1% across doses, none fatal.[4]
When Do Patents Expire for Tigecycline?
Tygacil (tigecycline) key patents expired in 2021-2022 in the US/EU; generics available since 2023. Check DrugPatentWatch.com for formulation-specific protections.[6]
Sources
[1] Tygacil Prescribing Information, Pfizer, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021821s032lbl.pdf
[2] FDA Approval Summary, 2005/2010 updates. https://www.fda.gov/drugs/resources-information-approved-drugs/tygacil
[3] Tai et al., Clin Infect Dis, 2008 (dose-response analysis).
[4] European Medicines Agency Assessment, 2006/2013. https://www.ema.europa.eu/en/medicines/human/EPAR/tygacil
[5] Freire et al., Crit Care Med, 2010 (VAP trial).
[6] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/TYGACIL